Vaccine plus pembrolizumab before surgery for early colon cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This phase 2 trial tests whether injecting a vaccine into the tumor, along with pembrolizumab (an immune medicine), can improve outcomes for people with early-stage, localized colon cancer that does not have certain DNA mismatch repair changes (pMMR). It’s done around the time you plan to have curative surgery, with the goal of boosting the immune system against the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and can sign consent in writing.
- You have localized colon cancer (stage I to III) confirmed by biopsy/pathology and it is pMMR (not dMMR).
- You are scheduled for planned curative surgery without getting chemotherapy/radiation before surgery.
- Your general health is good (ECOG 0 or 1), meaning you’re able to do most daily activities.
- Your blood counts, kidney function, and liver function meet lab thresholds (examples: hemoglobin, neutrophils, platelets, and kidney/liver lab limits).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach for people with locally advanced low rectal cancer that is pMMR type. You would receive a combination of an immunotherapy drug (anti-PD-1) with chemotherapy (FOLFOXIRI) and radiation before any surgery, to try to shrink the tumor as much as possible.
This trial tests a new immunotherapy drug called serplulimab combined with standard chemotherapy or targeted therapy for colorectal cancer that has come back within a year after surgery. The goal is to see if adding this immune-boosting drug helps control the cancer better than chemotherapy alone.
This trial tests if the immunotherapy drug pembrolizumab can shrink colon cancers with specific genetic features (dMMR/MSI-H) before surgery. If the tumor responds well, some patients might avoid chemotherapy after surgery. It is for people with newly diagnosed, localized colon or upper rectal cancer.
This trial tests whether giving immunotherapy (pembrolizumab) before surgery can help treat stage I-III colon cancer that has a specific genetic feature (dMMR). The goal is to see if this approach can reduce the amount of surgery needed or improve outcomes.
This trial tests pembrolizumab (an immunotherapy medicine) given before curative surgery in people with certain MMR-deficient colon or rectal cancers. It aims to shrink or control the cancer so surgery can be done more effectively, and to see if outcomes improve compared with standard care.
This trial tests whether giving chemotherapy followed by an immunotherapy drug (a checkpoint inhibitor) before surgery helps shrink locally advanced colon cancer. It is for people with a specific tumor type (MSS and RAS mutation) who have not had prior treatment.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.